Skip to content
OpenCapital
Get started

LivaNova LIVN Neuromodulation — Selling, general, and administrative

Other segment segments

Cardiopulmonary
$59.85M+2.3%

Similar metrics at other companies

Boston Scientific logo
BSXNeuromodulation — Net Sales
$318M+17.3%
Medtronic logo
MDTNeuroscience — Selling, general, and administrative expense
$875M+7.6%
Thor Industries logo
THONorth American Motorized — SELLING, GENERAL AND ADMINISTRATIVE EXPENSES:
$34.69M+1.0%
Hayward Holdings logo
HAYWNAM — Segment selling, general and administrative expense
$45.47M+7.9%
Itron logo
ITRINetworked Solutions — Sales, general and administrative
$7.28M+9.0%
SSD
SSDAdministrative and all other — Selling expense
$0—

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's neuromodulation — selling, general, and administrative.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's neuromodulation — selling, general, and administrative?
LivaNova (LIVN) reported neuromodulation — selling, general, and administrative of $52.62M in Q1 2026.
How has LivaNova's neuromodulation — selling, general, and administrative changed year-over-year?
LivaNova's neuromodulation — selling, general, and administrative increased by 10.6% year-over-year, from $47.57M to $52.62M.
What is the long-term trend for LivaNova's neuromodulation — selling, general, and administrative?
Over 3 years (2022 to 2025), LivaNova's neuromodulation — selling, general, and administrative has grown at a 8.4% compound annual growth rate (CAGR), from $158.98M to $202.6M.
What does neuromodulation — selling, general, and administrative mean?
Captures the indirect costs associated with operating the Neuromodulation segment, including sales force compensation, marketing, and general corporate overhead. It reflects the level of investment required to support and grow the segment's market presence.